Some patients with non-small cell lung cancer (NSCLC) have mutations in a gene called human epidermal growth factor receptor 2 (HER2), which drives their disease progression. Treatment options are limited for patients with this rare mutation, with only AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu approved to target it.
The palms of our hands and the bottoms of our feet aren’t the flashiest body parts, but they have a secret superpower that we don’t often appreciate—the ability to bear weight.
Gentronix, a British contract research organization that specializes in genetic toxicology, is officially off the market. Danish CRO Scantox, with its majority owner Impilo, bought Gentronix and integrated the company into its toxicology operations, according to a Sept. 9 release.
Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to question whether the biotech has done enough to differentiate its asset and unseat the incumbent.
The recent decision to merge Genentech’s two cancer departments was made for “scientific reasons,” executives explained to the media this morning.
MBX has fleshed out plans to take in over $136 million from its IPO as the biotech looks to bring a potential challenger to Ascendis Pharma’s rare endocrine disease drug Yorvipath into phase 3.
The average rate on a 30-year mortgage in the U.S. has eased for the third week in a row
IRS leadership on Thursday announced that the agency has recovered $4.7 billion in back taxes and proceeds from a variety of crimes
Wholesale costs in the United States picked up sharply last month, signaling that price pressures are still evident in the economy even though inflation has tumbled from the peak levels it hit more than two years ago
U.S. applications for unemployment benefits jumped to their highest level in two months last week but remain low relative to historical standards
Weekly Market Review – December 21, 2024
Weekly Market Review – December 21, 2024
Medtronic appoints new chief medical officer for digital surgery and robotics
Neurocrine’s bid to save schizophrenia prospect fails
FDA greenlights over-the-counter hearing aid features for Apple’s AirPods
Oncternal folds all clinical trials after lackluster data drop, patient death
Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs
FDA pushed to be more open, collaborative to accelerate rare disease R&D
In wake of Q2 revenue drop, Charles River cuts 3% of workforce
Inflammatix collects $57M as it awaits FDA review of infectious disease test
